<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Aurinia Pharmaceuticals Inc — News on 6ix</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc</link>
<description>Latest news and press releases for Aurinia Pharmaceuticals Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 30 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/aurinia-pharmaceuticals-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683549af78dffbe2df0e45ba.webp</url>
<title>Aurinia Pharmaceuticals Inc</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc</link>
</image>
<item>
<title>Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-to-acquire-kezar-life-sciences-for-dollar6955-in-cash-per-share-plus-a-contingent-value-right</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-to-acquire-kezar-life-sciences-for-dollar6955-in-cash-per-share-plus-a-contingent-value-right</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Maryland & EDMONTON, Alberta & SOUTH SAN FRANCISCO, California--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a biopharmaceutical</description>
</item>
<item>
<title>Aurinia Announces Management Transition</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-announces-management-transition</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-announces-management-transition</guid>
<pubDate>Mon, 23 Mar 2026 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced today that Kevin Tang, Aurinia’s Chair of</description>
</item>
<item>
<title>Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-twelve-months-ended-december-31-2025-and-provides-update-on-recent-business-progress</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-reports-financial-results-for-the-three-and-twelve-months-ended-december-31-2025-and-provides-update-on-recent-business-progress</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and twelve</description>
</item>
<item>
<title>Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-twelve-months-ended-december-31-2025-and-provide-update-on-recent-business-progress-on-february-26-2026</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-to-report-financial-results-for-the-three-and-twelve-months-ended-december-31-2025-and-provide-update-on-recent-business-progress-on-february-26-2026</guid>
<pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
<description>ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for</description>
</item>
<item>
<title>Specific Biologics Welcomes Accomplished Biotechnology Leader Dr. Richard Glickman to its Board of Directors</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/specific-biologics-welcomes-accomplished-biotechnology-leader-dr-richard-glickman-to-its-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/specific-biologics-welcomes-accomplished-biotechnology-leader-dr-richard-glickman-to-its-board-of-directors</guid>
<pubDate>Tue, 16 Dec 2025 15:00:00 GMT</pubDate>
<description>Specific Biologics Inc. ("Specific Biologics"), a precision in vivo genome editing company developing highly predictable, efficient and specific Dualase® genome editors to treat the untreatable, today announced the appointment of Dr. Richard Glickman to its Board of Directors.</description>
</item>
<item>
<title>Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-reports-financial-results-three-and-nine-months-ended</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-reports-financial-results-three-and-nine-months-ended</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Third Quarter 2025 LUPKYNIS Sales Grew 27% LUPKYNIS Sales Guidance for 2025 Raised to $265 Million to $270 Million Aritinercept Advances Toward Clinical</description>
</item>
<item>
<title>Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-report-financial-results-three-and-nine-months-ended</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-report-financial-results-three-and-nine-months-ended</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will report financial results for</description>
</item>
<item>
<title>Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-announces-upcoming-presentations-new-data-lupkynisr-american-college</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-announces-upcoming-presentations-new-data-lupkynisr-american-college</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in</description>
</item>
<item>
<title>Aurinia Responds to Now Retracted LinkedIn Post</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-responds-now-retracted-linkedin-post-2025-09-30</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-responds-now-retracted-linkedin-post-2025-09-30</guid>
<pubDate>Mon, 29 Sep 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today responded to a now retracted LinkedIn post</description>
</item>
<item>
<title>Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2025</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-reports-financial-results-three-and-six-months-ended-june-30</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-reports-financial-results-three-and-six-months-ended-june-30</guid>
<pubDate>Thu, 31 Jul 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md.& EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three and six</description>
</item>
<item>
<title>Aurinia Pharmaceuticals to Release Second Quarter 2025 Financial and Operational Results on July 31, 2025</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-release-second-quarter-2025-financial-and-operational-results</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-release-second-quarter-2025-financial-and-operational-results</guid>
<pubDate>Tue, 22 Jul 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will</description>
</item>
<item>
<title>Aurinia Announces Positive Results from Phase 1 Study of Aritinercept (AUR200)</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-announces-positive-results-phase-1-study-aritinercept-aur200-2025-06-30</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-announces-positive-results-phase-1-study-aritinercept-aur200-2025-06-30</guid>
<pubDate>Mon, 30 Jun 2025 04:00:00 GMT</pubDate>
<description>Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins Pharmacodynamic Effects Supportive of Once-Monthly Dosing Plan to</description>
</item>
<item>
<title>Aurinia Pharmaceuticals to Host Conference Call to Discuss AUR200 Phase 1 Study Results on June 30, 2025</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-host-conference-call-discuss-aur200-phase-1-study-results</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-host-conference-call-discuss-aur200-phase-1-study-results</guid>
<pubDate>Sun, 29 Jun 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that it will host a webcast and conference</description>
</item>
<item>
<title>New AURORA 1 Analysis: LUPKYNIS-Based Triple Immunosuppressive Therapy Yields Deep Proteinuria Reduction in Lupus Nephritis</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/new-aurora-1-analysis-lupkynis-based-triple-immunosuppressive-therapy-yields-deep</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/new-aurora-1-analysis-lupkynis-based-triple-immunosuppressive-therapy-yields-deep</guid>
<pubDate>Thu, 22 May 2025 04:00:00 GMT</pubDate>
<description>LUPKYNIS Data Presented at LUPUS 2025, the 16th International Congress on SLE, May 21-24 ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia</description>
</item>
<item>
<title>Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-reports-financial-results-three-months-ended-march-31-2025</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-reports-financial-results-three-months-ended-march-31-2025</guid>
<pubDate>Mon, 12 May 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced financial results for the three months</description>
</item>
<item>
<title>Aurinia Pharmaceuticals to Release First Quarter 2025 Financial and Operational Results on May 12, 2025</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-release-first-quarter-2025-financial-and-operational-results</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/aurinia-pharmaceuticals-release-first-quarter-2025-financial-and-operational-results</guid>
<pubDate>Mon, 05 May 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that it will</description>
</item>
<item>
<title>Glass Lewis Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/glass-lewis-recommends-aurinia-shareholders-100000018</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/glass-lewis-recommends-aurinia-shareholders-100000018</guid>
<pubDate>Wed, 30 Apr 2025 10:00:00 GMT</pubDate>
<description>ROCKVILLE, Md. & EDMONTON, Alberta, April 30, 2025--Glass Lewis recommends that Aurinia Shareholders vote "FOR" all proposals at 2025 Annual General Meeting.</description>
</item>
<item>
<title>Glass Lewis Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/glass-lewis-recommends-aurinia-shareholders-vote-all-proposals-2025-annual-general</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/glass-lewis-recommends-aurinia-shareholders-vote-all-proposals-2025-annual-general</guid>
<pubDate>Wed, 30 Apr 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ: AUPH) today announced that leading</description>
</item>
<item>
<title>ISS Recommends That Aurinia Shareholders Vote "FOR" All Proposals at 2025 Annual General Meeting</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/iss-recommends-aurinia-shareholders-vote-100000969</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/iss-recommends-aurinia-shareholders-vote-100000969</guid>
<pubDate>Tue, 29 Apr 2025 10:00:00 GMT</pubDate>
<description>ROCKVILLE, Md. & EDMONTON, Alberta, April 29, 2025--ISS recommends that Aurinia Shareholders vote "FOR" all proposals at 2025 Annual General Meeting.</description>
</item>
<item>
<title>ISS Recommends That Aurinia Shareholders Vote “FOR” All Proposals at 2025 Annual General Meeting</title>
<link>https://6ix.com/company/aurinia-pharmaceuticals-inc/news/iss-recommends-aurinia-shareholders-vote-all-proposals-2025-annual-general-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/aurinia-pharmaceuticals-inc/news/iss-recommends-aurinia-shareholders-vote-all-proposals-2025-annual-general-meeting</guid>
<pubDate>Tue, 29 Apr 2025 04:00:00 GMT</pubDate>
<description>ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) (NASDAQ: AUPH) today announced that leading</description>
</item>
</channel>
</rss>